IFW

Docket No.: ACADIA.030A **Customer No. 20,995**



INFORMATION DISCLOSURE STATEMENT

Applicant	:	David M. Weiner, et al.
App. No	:	10/759,561
Filed	:	January 15, 2004
For	:	SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES
Examiner	:	Leonard M. Williams
Art Unit	:	1617

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 6, 2007
(Date)

Ryan E. Melnick, Reg. No. 58,621

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 181 references to be considered by the Examiner. Also enclosed are 154 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

With respect to Reference 34, an English translation was not available. However, Reference 76 filed herewith, is believed to contain the relevant portions in English.

With respect to Reference 31, an English translation was not available. However, U.S. Patent No. 5,025,013, Reference 7 filed herewith, is believed to contain the relevant portions in English.

With respect to Reference 54, an English translation was not available. However, U.S. Patent Publication No. 2004-0106600 A1 at paragraph [0247] on page 15, filed with the IDS dated January 29, 2007 (Reference 8) is believed to contain a concise explanation of the relevance of the reference.

With respect to Reference 62, an English translation was not available. However, U.S. Patent No. 6,911,452 at column 18, lines 24-42, filed with the IDS dated January 29, 2007 (Reference 5), is believed to contain a concise explanation of the relevance of the reference.

With respect to Reference 83 an English translation was not available. However, Applicants believe the relevant portions are the chemical structure shown therein.

With respect to Reference 127, an English translation was not available. However, U.S. Patent Publication No. 2004-0106600 A1 at paragraph [0244] on page 15, filed with the IDS dated January 29, 2007 (Reference 8) is believed to contain a concise explanation of the relevance of the reference.

With respect to Reference 141, an English translation was not available. However, U.S. Patent Publication No. 2004-0106600 A1 at paragraph [0247] on page 15, filed with the IDS dated January 29, 2007 (Reference 8) is believed to contain a concise explanation of the relevance of the reference.

With respect to Reference 153, an English translation was not available. However, U.S. Patent Publication No. 2004-0106600 A1 at paragraph [0244] on page 15, filed with the IDS dated January 29, 2007 (Reference 8) is believed to contain a concise explanation of the relevance of the reference.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 8-6-07

By: Ryan Melnick

Ryan E. Melnick
Registration No. 58,621
Attorney of Record
Customer No. 20,995
(619) 235-8550

4101037:sad
080607

PTO/SB/08 Equivalent

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 1 OF 10	Attorney Docket No.	ACADIA.030A

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number *Number - Kind Code (if known)* Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	4,138,492	2/6/1979	Noverola, et al.	
	2	4,255,432	3/10/1981	Kluge, et al.	
	3	4,332,804	6/1/1982	Clark	
	4	4,353,900	10/12/1982	Clark	
	5	4,353,901	10/12/1982	Clark	
	6	4,367,232	1/4/1983	Boix-Igleasias, et al.	
	7	5,025,013	6/18/1991	Barreau, et al.	
	8	5,214,055	5/25/1993	Peglion, et al.	
	9	5,461,066	10/24/1995	Gericke, et al.	
	10	5,595,872	1/21/1997	Wetterau II, et al.	
	11	5,621,010	4/15/1997	Sueda, et al.	
	12	5,795,894	8/18/1998	Shue, et al.	
	13	5,869,488	2/9/1999	Shue, et al.	
	14	6,107,324	8/22/2000	Behan, et al.	
	15	6,140,509	10/31/2000	Behan, et al.	
	16	7,022,698	4/4/2006	Hamied, et al.	
	17	7,041,667	5/9/2006	Armour, et al.	
	18	2004/0213816 A1	10/28/2004	Weiner, et al.	
	19	2005/0148018 A1	7/7/2005	Weiner, et al.	
	20	2005/0244862 A1	11/3/2005	Brann	
	21	2006/0106063 A1	5/18/2006	Thygesen, et al.	
	22	2006/0111399 A1	5/25/2006	Thygesen, et al.	
	23	2006/0205780 A1	9/14/2006	Thygesen, et al.	
	24	2006/0205781 A1	9/14/2006	Thygesen, et al.	
	25	2006/0264466 A1	11/23/2006	Weiner, et al.	
	26	2006/0286610 A1	12/21/2006	Brann	
	27	2006/0292606 A1	12/28/2006	Brann	

Examiner Signature	Date Considered

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T[1] - Place a check mark in this area when an English language Translation is attached.

PTO/SB/08 Equivalent

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 2 OF 10	Attorney Docket No.	ACADIA.030A

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document *Country Code-Number-Kind Code* Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T[1]
	28	CA 984843	3/2/1976	John Wyeth & Brother Limited		
	29	EP 0 005 318 A1	11/14/1979	Janssen Pharm.		
	30	EP 0 061 333 A1	9/29/1982	Syntex (U.S.A.) Inc.		
	31	EP 0 379 441 A1	7/25/1990	Rhone-Poulenc Sante		
	32	EP 0 548 015 A1	6/23/1993	Ciba-Geigy AG		
	33	EP 0 625 507 A2	11/23/1994	Nisshin Flour Milling Co., Ltd.		
	34	HU 157325	3/19/1998	Rudolf, et al.		
	35	WO 97/08166 A1	3/6/1997	Schering Corporation		
	36	WO 97/11940 A1	4/3/1997	Eli Lilly and Company		
	37	WO 98/11128 A1	3/19/1998	Dr. Karl Thomae GMBH		
	38	WO 98/17646 A1	4/30/1998	Dr. Karl Thomae GMBH		
	39	WO 98/44921 A1	10/15/1998	Merck & Co., Inc.		
	40	WO 99/52927 A1	10/21/1999	Arena Pharmaceuticals, Inc.		
	41	WO 00/23076 A1	4/27/2000	Suntory Limited		
	42	WO 00/56335 A1	9/28/2000	The Regents of the University of California		
	43	WO 00/69810 A1	11/23/2000	Novo Nordisk A/S		
	44	WO 01/44191 A1	6/21/2001	Societe de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.)		
	45	WO 01/87839 A1	11/22/2001	Astrazeneca AB		
	46	WO 02/079186 A2	10/10/2002	F. Hoffman-La Roche AG		
	47	WO 03/070246 A1	8/28/2003	Pfizer Products Inc.		
	48	WO 2005/112927 A	12/1/2005	Acadia Pharmaceuticals Inc.		
	49	WO 2006/036874 A1	4/6/2006	Acadia Pharmaceuticals Inc.		
	50	WO 2006/037043 A1	4/6/2006	Acadia Pharmaceuticals Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[1]

Examiner Signature	Date Considered

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T[1] - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 3 OF 10	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[1]
	51	ADAM, et al. 1989. Effects of repeated ritanserin on middle-aged poor sleepers. *Psychopharmacology*, 99:219-221.	
	52	ADELL, et al. 2005. Strategies for producing faster acting antidepressants. *Drug Discovery Today*, 10(8):578-585.	
	53	AKIN, et al. 2004. Decreased serotonin 5-HT_{2A} receptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients. *Neuropsychopharmacology*, 29:2081-2087.	
	54	ALVISI, N. 1892. Sulla formazione di derivati pirazolici dalle dicloridrine e dalla tribromidrina della glicerina ordinaria, *Gazz. Chem. Ital.* 22:158-168.	
	55	ANTILLA, et al. 2001. Copper-catalyzed coupling of arylboronic acids and amines. *Organic Letters*, 3(13):2077-2079.	
	56	ANTILLA, et al. 2002. The copper-catalyzed *N*-arylation of indoles. *J. Am. Chem. Soc.*, 124:11684-11688.	
	57	ARCHIBALD, et al., 1974 "Benzamidopiperdines. 2. Heterocyclic Compounds Related to Indoramin" *J. Medicinal Chemistry*, 17(7):736-739	
	58	ARCHIBALD, et al., 1974 "Benzamidopiperdines. 3. Heterocyclic Compounds Related to Indoramin" J. Medicinal Chemistry, 17(7):-739-744	
	59	ARCHIBALD, et al., 1974 "1,4-Bis-(2-indol-3-ylethyl)piperdines" J. Medicinal Chemistry, 17(7):-745-747	
	60	ARTICO, et al. 1992. Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase. *Eur. J. Med. Chem.*, 27:219-228.	
	61	BAKSHI, et al. 1994. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. *The Journal of Pharmacology and Experimental Therapeutics*, 271(2):787-794.	
	62	BASSUS, et al. 1974. Psychotropes potentiels. X. Synthèse de butyrophénones à cycle pipéridine-spiro-tétrahydrooxazinone douées d'activité neuroleptique. *Eur. J. Med. Chem. – Chimica Therapeutica*, 9(4):416-423.	
	63	BHATIA, et al. 1996. 5-Lipoxygenase inhibitors: Synthesis and structure-activity relationships of a series of 1-Aryl-2*H*,4*H*-tetrahydro-1,2,4-triazin-3-ones. *J. Med. Chem.*, 39:3938-3950.	
	64	BIAGI, et al. 1988. 1,2,3-Triazoles: Structural changes on two effective inhibitors of the prostaglandin synthesis *in vitro*. *Farmaco Ed. Sci.*, 43:597-612.	
	65	BLAKLEY, et al. 2001. Bidirectional changes in ethanol consumption in rats with site-specific antisense down-regulation of 5-hydroxytryptamine$_{2A}$ receptors in brain. *The Journal of Pharmacology and Experimental Therapeutics*, 299(1):277-289.	
	66	BLIER, et al. 2001. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. *Journal of Psychiatry & Neuroscience*, 26(1):37-43.	
	67	BLIER, et al. 2005. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. *J. Clin. Psychiatry*, 66(suppl 8):30-40.	
	68	BROWN, et al. 1924. Catalytic alkylation of aniline, *J. Am. Chem. Soc.*, 46(8):1836-1839.	
	69	BUCHI et al. 1969. Synthesis of (±)-nuciferal. *J. Org. Chem.*, 34(4):1122-1123.	

Examiner Signature	Date Considered

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T[1] - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		
	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 4 OF 10	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[1]
	70	BUU-HOI, et al. 1951. Further studies in the alkylation of phenols and thiophenols, *J. Org. Chem.*, 16:988-994.	
	71	CACCHI, et al. 2003. Palladium-catalyzed reaction of aryl iodides with acetic anhydride. A carbon monoxide-free synthesis of acetophenones. *Organic Letters*, 5(3):289-291.	
	72	CARMAN, et al. 1998. A further synthesis of an analogue of the antifuncal/antiherbivore lipid from avocado. *Aust. J. Chem.*, 51:955-959.	
	73	CAROON, et al. 1981. Synthesis and antihypertensive activity of a series of 8-substituted 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones. *J. Med. Chem.*, 24:1320-1328.	
	74	CARROLL, et al. 1992. Synthesis and muscarinic receptor activity of ester derivatives of 2-substituted 2-azabicyclo[2.2.1]heptan-5-ol and –6-ol. *J. Med. Chem.*, 35:2184-2191.	
	75	CATARZI, et al. 2001. Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,4-triazolo[1,5-*a*]quinoxaline-2-carboxylates analogues of TQX-173. *J. Med Chem.*, 44:3157-3165.	
	76	Chemical Abstracts, 73:25305. BENKE, et al. 1970.	
	77	CHERKASOV, et al. 1985. Organothiophosphorus reagents in organic synthesis. *Tetrahedron*, 41(13):2567-2624.	
	78	CLARK et al. 1983. Antihypertensive 9-substituted 1-Oxa-4,9-diazaspiro[5.5]undecan-3-ones. *J. Med. Chem.*, 26:855-861.	
	79	CLIFTON, et al. 1982. Arylethanolamines Derived from Salicyclamide with α- and β-Adrenoceptor Blocking Activities. Preparation of Labetalol, its Enantiomers, and Related Salicyclamides. *J. Med.Chem.*, 25:670-679.	
	80	DeCLERCK, et al. 1987. Increase in slow-wave sleep in humans with the serotonin-S_2 antagonist ritanserin. *Current Therapeutic Research*, 41(4):427-432.	
	81	DUNN, et al. 1986. Analgetic and antiinflammatory 7-aroylbenzofuran-5-ylacetic acids and 7-aroylbenzothiophene-5-ylacetic acids. *J. Med. Chem.*, 29:2326-2329.	
	82	EMERSON, et al. 1938. The reductive alkylation of aniline. *J. Am. Chem. Soc.*, 60:2023-2025.	
	83	ERMAKOV, et al. 1981. Use of Mass spectrometry in structural and stereochemical studies. *Chemistry of Heterocyclic Compounds*, 1:72-77.	
	84	FINAR, et al. 1954. The preparation and properties of some derivatives of 1-phenylpyrazole, *J. Chem. Soc.*, pp. 2293-2298.	
	85	FIŠERA, et al. 1994. Synthesis of spiro-substituted 1,3-oxazines by a new sequence leading to spiroheterocycles. *Monatshefte für Chemie*, 125:909-919.	
	86	GAINETDINOV, et al. 2001. Genetic animal models: Focus on schizophrenia. *Trends in Neurosciences*, 24(9)527-533.	
	87	GAWLEY, R. E., & Aubé, J. 1996. *Principles of Asymmetric Synthesis*. New York: Pergamon.	

Examiner Signature	Date Considered

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T[1] - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		
	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 5 OF 10	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[1]
	88	GILLMAN, P. K. 2005. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. *British Journal of Anaesthesia*, 95(4):434-441.	
	89	GOOßEN, et al. 2001. Palladium-catalyzed synthesis of aryl ketones from boronic acids and carboxylic acids or anhydrides. *Angew. Chem. Int. Ed.*, 40:3458-3460.	
	90	GSTACH et al. 1990. Rearrangement of 3,3-disubstituted 1-aryl-4,5-dihydro-5-oxo-3*H*-1,2,4-triazolium tetraflluoroborates; Part 1. A versatile synthesis of 1,5-disubstituted 2-aryl-1,2-dihydro-3*H*-1,2,4-triazol-3-one tetrafluoroborates. *Synthesis,* pp. 803-808.	
	91	GUTHRIE, et al. 1993. The tetrahedral intermediate from the hydration of *N*-methylformanilide. *Can. J. Chem.*, 71:2109-2122.	
	92	HARPER, et al. 1964. The chemistry and pharmacology of some 4-aminopiperidines and their derivatives. *J. Med. Chem.*, 44:729-732.	
	93	HARTWIG, J. F. 1998. Transition metal catalyzed synthesis of arylamines and aryl ethers from aryl halides and triflates: Scope and mechanism. *Angew. Chem. Int. Ed.*, 37:2047-2067.	
	94	HICKINBOTTOM, W. J. 1930. The preparation of secondary alkylaryl-amines and their purification. *J. Chem. Soc.*, pp. 992-994.	
	95	HIRST, et al. 1895. A method for preparing the formyl derivatives of the aromatic amines. *J. Chem. Soc.*, 67:829-831.	
	96	IDZIKOWSKI, et al. 1991. A dose response study examining the effects of ritanserin on human slow wave sleep. *Br. J. Clin. Pharmac.*, 31:193-196.	
	97	IRIKURA et al., 1971 "New Anticulcer Agents. 1. Synthesis and Biological Activities of 1-Acyl-2-,-3-, -4-substituted Benzamidopiperdines" *J. Medicinal Chemistry* 14(4): 357-361	
	98	JAEGER, et al. 1941. Two ketones of the stilboestrol group. *J. Chem. Soc.*, 744-747.	
	99	KANAYAMA, et al. 2005. New treatment of lumbar disc herniation involving 5-hydroxytryptamine$_{2A}$ receptor inhibitor: A randomized controlled trial. *J. Neurosurg: Spine*, 2:441-446.	
	100	KLAPARS, et al. 2001. A general and efficient copper catalyst for the amidation of aryl halides and the *N*-arylation of nitrogen heterocycles. *J. Am. Chem. Soc.*, 123:7727-7729.	
	101	KLAPARS, et al. 2002. A general and efficient copper catalyst for the amidation of aryl halides. *J. Am. Chem. Soc.*, 124:7421-7428.	
	102	KUEHNE, et al. 1991(a). Enantioselective syntheses of vinblastine, leurosidine, vincovaline, and 20'-*epi*-vincovaline. *J. Org. Chem.*, 56(2):513-528.	
	103	KUEHNE, et al. 1991(b). Total syntheses of *Yohimbe* alkaloids, with stereoselection for the normal, allo, and 3-epiallo series, based on annelations of 4-methoxy-1,2-dihydropyridones. *J. Org. Chem.*, 56(8):2701-2712.	
	104	KWONG, et al. 2002(a). Copper-catalyzed coupling of alkylamines and aryl iodides: An efficient system even in an air atmosphere. *Organic Letters,* 4(4):581-584.	
	105	KWONG, et al. 2002(b). A general, efficient, and inexpensive catalyst system for the coupling of aryl iodides and thiols. *Organic Letters,* 4(20):3517-3520.	

Examiner Signature	Date Considered

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T[1] - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		
	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 6 OF 10	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[1]
	106	KWONG, et al. 2003. Mild and efficient copper-catalyzed amination of aryl bromides and primary alkylamines. *Organic Letters,* 5(6):793-796.	
	107	LANDINI, et al. 1974. A convenient synthesis of primary and secondary dialkyl and aryl alkyl sulfides in the presence of phase-transfer catalysts. *Synthesis*, pp. 565-566.	
	108	LANDOLT, et al. 1999. Serotonin-2 receptors and human sleep: Effect of a selective antagonist on EEG power spectra. *Neuropsychopharmacology*, 21(3):455-466.	
	109	LI, G. Y. 2002. Highly active, air-stable palladium catalysts for the C-C and C-S bond-forming reactions of vinyl and aryl cholrides: Use of commercially available $[(t\text{-Bu})_2P(OH)]_2PdCl_2$, $[(t\text{-Bu})_2P(OH)PdCl_2]_2$, and $[[(t\text{-Bu})_2PO...H...OP(t\text{-Bu})_2]PdCl]_2$ as catalysts. *J. Org. Chem.*, 67:3643-3650.	
	110	LOWE, et al. 1994. Aza-tricyclic substance P antagonists. *J. Med. Chem.*, 37:2831-2840.	
	111	MANSBACH, et al. 1988. Dopaminergic stimulation disrupts sensorimotor gating in the rat. *Psychopharmacology*, 94:507-514.	
	112	MAREK, et al. 2003. Synergistic action of 5-HT_{2A} antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. *Neuropsychopharmacology*, 28:402-412.	
	113	MAREK, et al. 2005. The selective 5-HT_{2A} receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. *Neuropsychopharmacology*, 30:2205-2215.	
	114	MAVUNKEL, et al. 1996. Synthesis and characterization of pseudopeptide bradykinin B2 receptor antagonists containing the 1,3,8-triazaspiro[4.5]decan-4-one ring system. *J. Med. Chem.*, 39:3169-3173.	
	115	MAYER, et al. 2003. Ritanserin improves sleep quality in narcolepsy. *Pharmacopsychiatry*, 364:150-155.	
	116	MELTZER, H. Y. 1999. The role of serotonin in antipsychotic drug action. *Neuropsychopharmacology*, 21(2S):106S-115S.	
	117	MENG, et al. 1991. Synthetic approaches toward glidobamine, the core structure of the glidobactin antibiotics. *Tetrahedron*, 47(32):62510-6264.	
	118	MICOVIC, et al. 1991. A simple method for preparation of secondary aromatic amines. *Synthesis*, 11:1043-1045.	
	119	MIYATA, et al. 2000. Sarpogrelate, a selective 5-HT_{2A} serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. *Journal of Cardiovascular Pharmacology*, 35(2) 294-301.	
	120	MÖHRLE, et al. 1990. Sodium mercury edetate dehydrogenation of N-aliphatic substituted 1,2,3,6-tetrahydropyridine derivatives. *Arch. Pharm. (Weinheim)*, 323:109-115.	
	121	MOUNE, et al. 1997. Total synthesis of dolatrienoic acid: A subunit of dolastatin 14. *J. Org. Chem.*, 62:3332-3339.	
	122	MULLEN et al. 2000. (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the α7 nicotinic acetylcholine receptor. *J. Med. Chem.*, 43:4045-4050.	
	123	MURI, et al. 1998. Synthesis of new benzylic ethers of oximes derived from 1-phenyl-pyrazole compounds. *Synthetic Communications*, 28(7):1299-1321.	

Examiner Signature	Date Considered

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T[1] - Place a check mark in this area when an English language Translation is attached.

PTO/SB/08 Equivalent

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		
	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 7 OF 10	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[1]
	124	NIGAM, et al. 1957a. Studies with acetylenes. Part II. Some reactions of Grignard reagents with propargylic halides. Model linoleic and linolenic acid systems. *J. Chem Soc.*, pp. 3868-3873.	
	125	NIGAM, et al. 1957b. The conversion of fatty acids into aldehydes. *J. Chem. Soc.*, pp.3320-3321.	
	126	OGAWA, et al. 2005. Effects of R-102444 and its active metabolite R-96544, selective 5-HT2A receptor antagonists, on experimental acute and chronic pancreatitis: Additional evidence for possible involvement of 5-HT2A receptors in the development of experimental pancreatitis. European Journal of Pharmacology, 521:156-163	
	127	OLAH, et al. 1956. Notiz über die *n*-formylierung von aminen mit formylfluorid. *Chem. Ber.*, 89:2211-2212.	
	128	OLD, et al. 2002. Efficient palladium-catalyzed *n*-arylation of indoles. *Organic Letters*, 2(10):1403-1406.	
	129	PAIVA, et al. 1988. Effects of ritanserin on sleep disturbances of dysthymic patients. *Psychopharmacology*, 96:395-399.	
	130	PATEL, et al. 2004. The highly selective 5-hydroxytryptamine $(5\text{-HT})_{2A}$ receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in male congenital learned helpless rats in the forced swim test. *Synapse*, 52:73-75.	
	131	PIERCE, et al. 1995. 5-hydroxytryptamine-induced synovial plasma extravasation is mediated *via* 5-hydroxytryptamine2A receptors on sympathetic efferent terminals. *The Journal of Pharmacology and Experimental Therapeutics*, 275(1):502-508.	
	132	READ, W. T. 1922. Researches on hydantoins. Synthesis of the soporific, 4,4-phenylethyl-hydantoin(nirvanol). *J. Am. Chem. Soc.*, 44:1746-1755.	
	133	RICCI, A. 2000. *Modern Animation Methods*. New York: Wiley-VCH.	
	134	RICE, et al. 1955. Raney nickel catalyzed n-alkylation of aniline and benzidine with alcohols. *J. Am. Chem. Soc.*, 77:4052-4054.	
	135	RUBIRALTA, M., Giralt, E., & Diez, A. 1991. *Studies in Organic Chemistry 43. Piperidine: Structure, Preparation, Reactivity and Synthetic Applications of Piperidine and its Derivatives.* New York: Elsevier.	
	136	SCHEIBYE, et al. 1978. Studies on organophosphorus compounds XXI. The dimer of *p*-methoxyphenylthionophosphine sulfide as thiation reagent. A new route to thiocarboxamides. *Bull. Soc. Chim. Belg.*, 87:229-238.	
	137	SCHINS, et al. 2003. Increased coronary events in depressed cardiovascular patients: 5-HT_{2A} receptor as missing link? *Psychosomatic Medicine*, 65:729-737.	
	138	SCRETTAS, et al. 1978. Hydrolithiation of α-olefins by a regiospecific two-step process. Transformation of alkyl phenyl sulfides to alkyllithium reagents. *J. Org. Chem.*, 43(6):1064-1071.	
	139	SHARPLEY, et al. 1994. Slow wave sleep in humans: Role of 5-HT_{2A} and 5-HT_{2C} receptors. *Neuropharmacology*, 33(3/4):467-471.	
	140	SMITH, et al. 1995. New spiropiperdines as potent and selective non-peptide tachykinin NK_2 receptor antagonists. *J. Med. Chem.*, 38(19):3772-3779.	

Examiner Signature	Date Considered

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T[1] - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 8 OF 10	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[1]
	141	STEFANCICH, et al. 1984. Agenti antiinfiammatori non-steroidei: Nota III – sintesi ed attività analgesica-antiinfiammatoria di 4-(pirrol-1-il)-fenilacetamidi e di 4-(pirrol-1-il)fenetilamine. *Farmaco Ed. Sci.*, 39(9):752-764.	
	142	STRYJER, et al. 2003. Treatment of neuroleptic-induced akathisia with the 5-HT_{2A} antagonist trazodone. *Clinical Neuropharmacology*, 26(3):137-141.	
	143	TOLSTIKOV et al.1991 "Synthesis and Reactivity of N-substituted aminoamides, antiarrhythmic and local anaesthetic activity" *Russian Chemical Reviews* 60(4):420434	
	144	TSUKAMOTO, et al. 1995. Synthesis and structure-activity studies of a series of 1-oxa-2,8-diazaspiro[4.5]decan-3-ones and related compounds as M_1 muscarinic agonists. *Chem. Pharm. Bull.*, 43(9):1523-1529.	
	145	VAN LAAR, et al. 2001. Subchronic effects of the GABA-agonist lorazepam and the 5-$HT_{2A/2C}$ antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. *Psychopharmacology*, 154:189-197.	
	146	VARMA, et al. 1999. Microwave-accelerated solvent-free synthesis of thioketones, thiolactones, thioamides, thionoesters, and thioflavonoids. *Organic Letters*, 1(5):697-700.	
	147	VIOLA, et al. 2002. Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers. *Clinical Neurophysiology*, 113:429-434.	
	148	VOGEL, A. I. 1948. Physical properties and chemical constitution. Part XIX. Five-membered and six-membered carbon rings. *J. Chem. Soc.*, pp. 1809-1813.	
	149	VOGL, et al. 2002. Palladium-catalyzed monoarylation of nitroalkanes. *J. Org. Chem.*, 67(1):106-111.	
	150	WADE, et al. 2000. Application of base cleavable safety catch linkers to solid phase library production. *J. Comb. Chem.*, 2(3):266-275.	
	151	WHITMORE, et al. 1942. Abnormal Grignard reactions. XII. Sterically hindered aliphatic carbonyl compounds. II. Ketones containing the dineopentylcarbinyl group. *J. Am. Chem. Soc.*, 64:1247-1251.	
	152	WHITMORE, et al. 1947. Higher hydrocarbons. IV. Six phenyleicosanes and six cyclohexyleicosanes. *J. Am. Chem. Soc.*, 69:235-237.	
	153	WOLF, V. V. 1952. Über alkin-amine I. Aryl-propargyl-amine. *Liebigs Ann. Chem.*, 576:35-45.	
	154	WOLFE, et al. 1996. An improved catalyst system for aromatic carbon-nitrogen bond formation: The possible involvement of bis(phosphine) palladium complexes as key intermediates. *J. Am. Chem. Soc.*, 118:7215-7216.	
	155	YAMADA, et al. 1998. Alternative synthesis of TTF donors with a dioxolane ring, and synthesis of their dithiolane and oxathiolane analogues. *Tetrahedron Letters*, 39:7709-7712.	
	156	YANG, et al. 1999. Palladium-catalyzed amination of aryl halides and sulfonates. *Journal of Organometallic Chemistry*, 576:125-146.	
	157	YASUHARA, et al. 2000. An activated phosphate for an efficient amide and peptide coupling reagent. *J. Chem. Soc., Perkin Trans. 1*, 17:2901-2902.	
	158	YIN, et al. 2002. Pd-catalyzed intermolecular amidation of aryl halides: The discovery that xantphos can be trans-chelating in a palladium complex. *J. Am. Chem. Soc.*, 124:6043-6048.	

Examiner Signature	Date Considered

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T[1] - Place a check mark in this area when an English language Translation is attached.

PTO/SB/08 Equivalent

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		
	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 9 OF 10	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[1]
	159	Notice of Allowance and Fee(s) Due and Notice of Allowability dated May 15, 1997, from Application No. 08/273,669 filed July 12, 1994, now U.S. Pat. No. 5,707,798.	
	160	Office Action dated March 27, 1998, from Application No. 08/954,724 filed October 20, 1997, now U.S. Pat. No. 5,912,132.	
	161	Notice of Allowance and Fee(s) Due and Notice of Allowability dated September 4, 1998, from Application No. 08/954,724 filed October 20, 1997, now U.S. Pat. No. 5,912,132.	
	162	Office Action dated September 14, 1998, from Application No. 08/965,947 filed November 7, 1997, now U.S. Pat. No. 5,955,281.	
	163	Interview Summary dated November 17, 1998, from Application No. 08/965,947 filed November 7, 1997, now U.S. Pat. No. 5,955,281.	
	164	International Search Report dated July 17, 2001 for PCT/US01/07187.	
	165	Written Opinion dated November 22, 2002 for PCT/US01/07187.	
	166	Office Action dated February 28, 2001, from Application No. 09/413,626 filed October 6, 1999, now U.S. Pat. No. 6,358,698.	
	167	Notice of Allowance and Fee(s) Due and Notice of Allowability dated November 20, 2001, from Application No. 09/413,626 filed October 6, 1999, now U.S. Pat. No. 6,358,698.	
	168	Office Action dated January 17, 2006, from Application No. 11/154,083 filed June 26, 2005.	
	169	International Search Report dated May 8, 2003 for PCT/US02/41476.	
	170	International Search Report dated January 30, 2006, for PCT/US2005/034813	
	171	Written Opinion of the International Searching Authority dated January 30, 2006, for PCT/US2005/034813.	
	172	International Search Report dated January 30, 2006, for PCT/US2005/034376.	
	173	Written Opinion of the International Searching Authority dated January 30, 2006, for PCT/US2005/034376.	
	174	Office Action dated November 4, 2004, from Application No. 10/601,070 filed June 20, 2003	
	175	International Preliminary Report on Patentability dated March 27, 2007, for PCT/US2005/034376.	
	176	International Preliminary Report on Patentability dated March 27, 2007, for PCT/US2005/034813.	
	177	Office Action dated April 6, 2007, from Application No. 11/418,322 filed May 3, 2006.	

Examiner Signature	Date Considered

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T[1] - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/759,561
	Filing Date	January 15, 2004
	First Named Inventor	David M. Weiner, et al.
	Art Unit	1617
(Multiple sheets used when necessary)	Examiner	Williams, Leonard M.
SHEET 10 OF 10	Attorney Docket No.	ACADIA.030A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[1]
	178	Office Action dated May 8, 2007, from Application No. 11/417,866 filed May 3, 2006.	
	179	Notice of Allowance and Fee(s) Due and Notice of Allowability dated March 5, 2007, from Application No. 10/601,070 filed June 20, 2003.	
	180	Office Action dated February 5, 2007, from Application No. 11/299,566 filed December 12, 2005	
	181	Notice of Allowance and Fee(s) Due and Notice of Allowability dated June 19, 2007, from application No. 11/418,322 filed May 3, 2006	

4095912:sad
080307

Examiner Signature	Date Considered

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T[1] - Place a check mark in this area when an English language Translation is attached.